

CITATION REPORT

List of articles citing

Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy

DOI: 10.4065/78.10.1207

Mayo Clinic Proceedings, 2003, 78, 1207-13.

Source: <https://exaly.com/paper-pdf/35340275/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
105	The mouse through the looking glass: a new door into the pathophysiology of pulmonary hypertension. 2004 , 94, 1001-4		27
104	Potential role for sildenafil in the management of perioperative pulmonary hypertension and right ventricular dysfunction after cardiac surgery. 2004 , 93, 155-6		18
103	Pulmonary hypertension. 2004 , 29, 575-634		16
102	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. 2004 , 25, 2243-78		665
101	Efficacy of Oral Sildenafil as Rescue Therapy in Patients With Severe Pulmonary Arterial Hypertension Chronically Treated With Prostacyclin. Long-Term Results. 2004 , 57, 946-951		2
100	Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. 2004 , 43, 81S-88S		137
99	Eficacia del sildenafilo por vĀ oral como terapia de rescate en pacientes con hipertensiĀ arterial pulmonar severa en tratamiento crĀico con prostaciclina. Resultados a largo plazo. 2004 , 57, 946-951		1
98	Treatment of pulmonary arterial hypertension. 2004 , 351, 1425-36		1338
97	Sildenafil: emerging cardiovascular indications. 2004 , 78, 1496-506		53
96	Lung transplantation: disease-specific considerations for referral. 2005 , 127, 1006-16		57
95	Lung transplant candidate selection and clinical outcomes: strategies for improvement in prioritization. 2005 , 10, 216-220		
94	Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. 2005 , 96, 47M-51M		150
93	Combination drug therapy in the management of pulmonary arterial hypertension. 2005 , 20, 177-82		4
92	Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. 2005 , 42, 219-32		155
91	Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. 2005 , 100, 131-8		150
90	Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. 2005 , 3, 26		26
89	Pulmonary artery hypertension: new drug treatment in children. 2005 , 90, ep15-ep20		1

88	Advances in the medical treatment of pulmonary hypertension. 2005 , 28, 311-24	4
87	Sildenafil citrate therapy for pulmonary arterial hypertension. 2005 , 353, 2148-57	1843
86	Sildenafil for pulmonary hypertension. 2005 , 39, 869-84	34
85	[Guidelines on diagnosis and treatment of pulmonary arterial hypertension]. 2005 , 58, 523-66	21
84	Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar. 2005 , 58, 523-566	
83	Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. 2006 , 20, 722-35	22
82	Effects of sildenafil citrate on defibrillation efficacy. 2006 , 17, 292-5	14
81	First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. 2006 , 36 Suppl 3, 32-8	54
80	New insights in the treatment strategy for pulmonary arterial hypertension. 2006 , 20, 377-86	23
79	[Beneficial effect of sildenafil following surgery for mitral stenosis complicated by pre-capillary pulmonary hypertension: report of two cases]. 2006 , 55, 286-90	1
78	Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years. 2006 , 26, 68-94	12
77	Sildenafil extends survival and graft function in a large animal lung transplantation model. 2006 , 29, 288-93	16
76	Classification and Prognosis of Pulmonary Arterial Hypertension. 2006 , 66-82	1
75	Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. 2006 , 96, 317-22	29
74	Pulmonary arterial hypertension: current therapeutic strategies. 2007 , 4, 319-29	46
73	Current Treatment of the Pulmonary Arterial Hypertension. 2007 , 3, 129-134	
72	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. 2007 , 15, 76-86	52
71	Management strategies for patients with pulmonary hypertension in the intensive care unit. 2007 , 35, 2037-50	204

70	Ischemic optic neuropathy in a child. 2007 , 37, 371-2	20
69	Evidence-based pharmacologic management of pulmonary arterial hypertension. 2007 , 29, 2134-53	67
68	Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. 2007 , 26, 363-9	25
67	Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. 2007 , 118, 178-82	31
66	Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. 2007 , 120, 306-13	52
65	Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. 2007 , 21, 203-7	34
64	Nonurologic applications of phosphodiesterase type 5 inhibitors. 2007 , 4, 64-70	1
63	Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. 2008 , 48, 926-34	86
62	Treating pulmonary hypertension post cardiopulmonary bypass in pigs: milrinone vs. sildenafil analog. 2008 , 23, 117-25	8
61	Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. 2008 , 105, 7028-33	97
60	Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca ²⁺ entry. 2008 , 108, 71-8	33
59	Guidelines for the diagnosis and treatment of pulmonary hypertension. 2009 , 34, 1219-63	919
58	Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. 2009 , 122, 216-38	273
57	Pulmonary hypertension in bronchopulmonary dysplasia. 2009 , 27, 43-48	35
56	Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. 2009 , 154, 379-84, 384.e1-2	196
55	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. 2009 , 26, 813-25	75
54	Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. 2009 , 30, 1-24	45
53	Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). 2009 , 30, 2193-537	2531

52	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. 2009 , 62, 1464.e1-1464.e58	1
51	First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. 2009 , 33, 785-92	186
50	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. 2009 , 62, 1464.e1-1464.e58	3
49	Efficacy of oral sildenafil in a beraprost-treated patient with severe pulmonary hypertension secondary to type I glycogen storage disease. 2009 , 73, 1965-8	14
48	Pharmacotherapeutic management of pulmonary arterial hypertension. 2010 , 18, 148-62	47
47	Noninvasive assessment of acute cardiopulmonary effects of an oral single dose of sildenafil in patients with idiopathic pulmonary hypertension. 2010 , 25, 313-8	7
46	Does sildenafil citrate affect myometrial contractile response to nifedipine in vitro?. 2010 , 203, 252.e1-5	9
45	Clinical use of sildenafil in pulmonary artery hypertension. 2010 , 4, 13-9	11
44	Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrrolidinyloxyethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. 2005 , 57, 1397-405	
43	Current therapeutic approaches to pulmonary arterial hypertension. 2010 , 63, 708-24	2
42	Estrategias terapéuticas actuales en la hipertensión arterial pulmonar. 2010 , 63, 708-724	15
41	Riociguat for pulmonary hypertension. 2010 , 6, 155-66	24
40	Riociguat for the treatment of pulmonary hypertension. 2011 , 20, 567-76	69
39	The value of tools to assess pulmonary arterial hypertension. 2011 , 20, 222-35	23
38	Pulmonary Vascular Disease and Bronchopulmonary Dysplasia: Evaluation and Treatment of Pulmonary Hypertension. 2011 , 12, e645-e651	8
37	Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits?. 2012 , 32, 64-9	65
36	Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. 2012 , 71, 1019-26	65
35	Pulmonary hypertension-"state of the art" management in 2012. 2012 , 64, 60-73	2

34	Pathways in pulmonary arterial hypertension: the future is here. 2012 , 21, 321-7	83
33	Orientações para o diagnóstico e tratamento da hipertensão pulmonar. 2012 , 31, 71-115	
32	Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. 2012 , 106, 730-9	20
31	The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. 2012 , 7, e43433	89
30	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. 2013 , 9, 1193-205	19
29	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension. 2014 , 9, S79-91	4
28	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Intensive care management of pulmonary hypertension. 2014 , 9, S121-6	4
27	Effect of sildenafil in the management of preoperative pulmonary hypertension Available online 22 June 2013 View all notes Peer review under responsibility of Alexandria University Faculty of Medicine. View all notes. 2014 , 50, 13-16	0
26	Improved survival in limited scleroderma-related pulmonary artery hypertension. 2014 , 9, 385-96	2
25	Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. 2016 , 32, 1520-1530	39
24	Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?. 2016 , 39, 131-42	18
23	PDE5 Inhibitors in Type 2 Diabetes Cardiovascular Complications. 2020 , 1, 90-101	2
22	The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis. 2021 , 31, 151-161	2
21	Sildenafil in endotoxin-induced pulmonary hypertension: an experimental study. 2021 ,	
20	Phosphodiesterase 5. 2006 ,	8
19	What's on the Horizon in Therapy, From Current Approaches to Experimental Agents. 2003 , 2, 9-16	2
18	Perioperative sildenafil therapy for children with ventricular septal defects and associated pulmonary hypertension undergoing corrective surgery: A randomised clinical trial. 2017 , 61, 798-802	2
17	Medical Treatment Options/Advances in Portopulmonary Hypertension: How the Spectrum Is Expanding. 2004 , 3, 17-22	

16	References. 2004 , 45-52		
15	Pulmonary Arterial Hypertension: Diagnostic Considerations. 2004 , 3, 4-23		1
14	Combination therapy using inhaled iloprost and sildenafil in a patient with idiopathic pulmonary arterial hypertension. 2007 , 49, 222-224		
13	Acute right heart failure. 2009 , 89-111		
12	Pulmonary Hypertension. 2009 , 893-918		
11	Approach to the Child With Pulmonary Hypertension and Bronchopulmonary Dysplasia. 2011 , 10, 98-103		1
10	Acute Right Heart Failure. 2017 , 209-271		
9	Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. 2005 , 32, 405-10		18
8	Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery. 2011 , 38, 238-42		30
7	Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. 2011 , 16, e30-5		39
6	Sildenafil Reduces Inflammation and Prevents Pulmonary Arterial Remodeling of the Monocrotaline - induced Disease in the Wistar Rats. 2012 , 7, 109-16		9
5	2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension. <i>Acta Cardiologica Sinica</i> , 2014 , 30, 401-44	1.1	11
4	Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension.. <i>Biomolecules</i> , 2022 , 12,	5.9	3
3	Assessment of disease outcome measures in systemic sclerosis. <i>Nature Reviews Rheumatology</i> ,	8.1	0
2	Quinazoline-based human phosphodiesterase 5 inhibitors exhibited a selective vasorelaxant effect on rat isolated pulmonary arteries involving NO-sGC-cGMP pathway and calcium inhibitory effects. 2022 , 107111		0
1	Management of pregnant patients with pulmonary arterial hypertension. 9,		0